Discover a study in which researchers examined three international cohorts of patients with moderate-to-severe psoriasis ...

For patients with psoriasis receiving biologic therapy, residual inflammation (RI), defined as increased inflammatory markers in blood, characterized by high-sensitivity C-reactive protein, despite ...

After a poor showing of its COVID med vilobelimab in a rare skin disorder trial, German drugmaker InflaRx is going back to ...

InflaRx’s vilobelimab met the bar for futility in a Phase III trial for the rare skin disease pyoderma gangrenosum.

Although the side effect is rare, the FDA said some patients experienced severe itching that required medical attention.

InflaRx ends its Phase 3 trial of vilobelimab in pyoderma gangrenosum and shifts focus to INF904 amid efforts to extend its ...

resulting in skin rashes, especially over the buttocks and behind the lower extremities. This is a rare syndrome that causes inflammation in the walls of arteries throughout the body, including ...

The disorder – driven by type 2 inflammation characterised by an antibody-based immune response – causes hard lumps or nodules to form on the skin that are so itchy they can lead patients to ...

MMP is a group of rare ... inflammation resulting in long-term tissue damage and cellular changes and repair associated with MMP, may be drivers of increased risk of certain skin cancers.

Lower doses of a common antibiotic can curb hair loss caused by a rare skin condition, a new study says. The antibiotic doxycycline is commonly used to treat lymphocytic scarring alopecia ...

Lower doses of a common antibiotic can curb hair loss caused by a rare skin condition ... without compromising the efficacy and anti-inflammatory benefit of the therapy," co-lead researcher ...